Literature DB >> 17636003

Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy.

Jinsook Kim1, Alexei Kondratyev, Karen Gale.   

Abstract

The aim of this study was to test the potential neurotoxicity of three antiepileptic drugs (AEDs), carbamazepine (5H-dibenzepine-5-carboxamide), topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-d-fructopyranose sulfamate], and levetiracetam [2-(2-oxopyrrolidin-1-yl)butanamide], in the developing rat brain, when given alone or in combinations. The extent of cell death induced by AEDs was measured in several brain regions of rat pups (postnatal day 8) by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 24 h after drug treatment. Carbamazepine alone did not increase neurodegeneration when given in doses up to 50 mg/kg, but it induced significant cell death at 100 mg/kg. When combined with phenytoin, carbamazepine, 50 but not 25 mg/kg, significantly exacerbated phenytoin-induced cell death. Although topiramate (20-80 mg/kg) alone caused no neurodegeneration, all doses exacerbated phenytoin-induced neurodegeneration. Levetiracetam (250-1000 mg/kg) alone did not induce cell death, nor did it exacerbate phenytoin-induced neurodegeneration. Of the combinations examined, only that of levetiracetam (250 mg/kg) with carbamazepine (50 mg/kg) did not induce neurodegeneration. Our data underscore the importance of evaluating the safety of combinations of AEDs given during development and not merely extrapolating from the effects of exposure to single drugs. Although carbamazepine and topiramate alone did not induce neuronal death, both drugs exacerbated phenytoin-induced cell death. In contrast, because cotreatment with levetiracetam and carbamazepine did not enhance cell death in the developing brain, it may be possible to avoid proapoptotic effects, even in polytherapy, by choosing appropriate drugs. The latter drugs, as monotherapy or in combination, may be promising candidates for the treatment of women during pregnancy and for preterm and neonatal infants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636003     DOI: 10.1124/jpet.107.126250

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Prenatal effects of antiepileptic drugs.

Authors:  Chrysanthy Ikonomidou
Journal:  Epilepsy Curr       Date:  2010-03       Impact factor: 7.500

2.  Effects of in utero antiepileptic drug exposure.

Authors:  Kimford J Meador
Journal:  Epilepsy Curr       Date:  2008 Nov-Dec       Impact factor: 7.500

3.  Melatonin potentiates the anticonvulsant action of phenobarbital in neonatal rats.

Authors:  Patrick A Forcelli; Colin Soper; Anne Duckles; Karen Gale; Alexei Kondratyev
Journal:  Epilepsy Res       Date:  2013-10-05       Impact factor: 3.045

Review 4.  Synergistic neuroprotective therapies with hypothermia.

Authors:  Maria Roberta Cilio; Donna M Ferriero
Journal:  Semin Fetal Neonatal Med       Date:  2010-03-07       Impact factor: 3.926

Review 5.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

6.  Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Authors:  S K Bhardwaj; P A Forcelli; G Palchik; K Gale; L K Srivastava; A Kondratyev
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

7.  Comparison of the long-term behavioral effects of neonatal exposure to retigabine or phenobarbital in rats.

Authors:  Sari Frankel; Natalia Medvedeva; Samuel Gutherz; Catherine Kulick; Alexei Kondratyev; Patrick A Forcelli
Journal:  Epilepsy Behav       Date:  2016-02-24       Impact factor: 2.937

Review 8.  Developmental effects of antiepileptic drugs and the need for improved regulations.

Authors:  Kimford J Meador; David W Loring
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

9.  Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats.

Authors:  Megan N Huizenga; Patrick A Forcelli
Journal:  Neurotox Res       Date:  2018-08-24       Impact factor: 3.911

10.  Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia.

Authors:  Davonna S Ledet; James W Wheless; Jeffrey E Rubnitz; E Brannon Morris
Journal:  Eur J Paediatr Neurol       Date:  2009-01-30       Impact factor: 3.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.